Open an account

Rapid Micro Biosystems

RPID · NASDAQ

$0.7717−$0.0019 (−0.25%)TodayMarket closed ·
Prev close $0.7736

About RPID

Rapid Micro Biosystems, Inc. is a life sciences technology company. The company is headquartered in Lexington, Massachusetts and currently employs 171 full-time employees. The company went IPO on 2021-07-15. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. The company offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.

Employees
171
Headquarters
Lexington, Massachusetts
Listed
Jul 15, 2021
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
rapidmicrobio.com

RPID key statistics

Market cap
38.71M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
272.06K
Volume
108.23K
Open price
$0.7612
High today
$0.82
Low today
$0.7612
52 Week high
$4.94
52 Week low
$0.76

Rapid Micro Biosystems (RPID) at a glance

Rapid Micro Biosystems (RPID) last traded at $0.7717, with a market cap of 38.71M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.7612 and $0.82. The current price is 1.4% above the day's low and 5.9% below its high.

Volume so far is 108.23K shares, below the average of 272.06K shares a day.

Over the past year Rapid Micro Biosystems has ranged from $0.76 to $4.94, and now sits 0% of the way up that range.

Rapid Micro Biosystems met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.27 per share against an estimate of -$0.2482.

The average analyst price target is $5.86, 660.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $5.86
Low
$3.03
Now
$0.7717
High
$8.40

RPID earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 4.0% on average.

  1. Q3 FY24: reported -$0.26 per share against an estimate of -$0.2601
  2. Q4 FY24: reported -$0.22 per share against an estimate of -$0.2346
  3. Q1 FY25: reported -$0.26 per share against an estimate of -$0.2754
  4. Q2 FY25: reported -$0.27 per share against an estimate of -$0.2584
  5. Q3 FY25: reported -$0.26 per share against an estimate of -$0.2499
  6. Q4 FY25: reported -$0.28 per share against an estimate of -$0.227
  7. Q1 FY26: reported -$0.31 per share against an estimate of -$0.2516
  8. Q2 FY26: reported -$0.27 per share against an estimate of -$0.2482

RPID news

  • Rapid Micro Biosystems Q1 2026 Earnings Call: Complete Transcript

  • Press releaseGlobe Newswire

    Rapid Micro Biosystems Reports First Quarter 2026 Financial Results

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Earnings Outlook For Rapid Micro Biosystems

  • Press releasePRNewswire

    Trinity Capital Inc. Provides $45 Million in Growth Capital to Rapid Micro Biosystems, Modernizing Healthcare Industry Practices

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releaseGlobe Newswire

    Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

  • A Look Ahead: Rapid Micro Biosystems's Earnings Forecast

Similar companies

Companies in the same industry as Rapid Micro Biosystems

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.